AHZ 0.95% $7.26 admedus ltd

News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-442

  1. 883 Posts.
    lightbulb Created with Sketch. 30


    Cant comment on the quality of the article, study or journal, (but its not the new idea......) however, as you sugegsted it highlights the additional conventiopnal costs that are reduced or elimianted with TAVR.


    While the TAVR hardware is many times more expensive ($30 k v $5k)...... the reduced costs and eliminations of OT, CP Bypass, reduced ICU recovery time, and overal length of stay, this article suggets that the procedure and hospital cost is slightly greater for TAVR (<$3000, or 5%) however, in the following two years, the conventional alternative is >$9000 or 9% more expensive than the TAVR approach.

    link below.


    https://www.mdedge.com/cardiology/article/150986/interventional-cardiology-surgery/tavr-wallops-savr-cost-effectiveness



 
watchlist Created with Sketch. Add AHZ (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.